See more : Cavitation Technologies, Inc. (CVAT) Income Statement Analysis – Financial Results
Complete financial analysis of IRadimed Corporation (IRMD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of IRadimed Corporation, a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Sojitz Corporation (SZHFF) Income Statement Analysis – Financial Results
- Beiersdorf Aktiengesellschaft (BDRFY) Income Statement Analysis – Financial Results
- IVD Medical Holding Limited (1931.HK) Income Statement Analysis – Financial Results
- Saudi Airlines Catering Company (6004.SR) Income Statement Analysis – Financial Results
- WalkMe Ltd. (WKME) Income Statement Analysis – Financial Results
IRadimed Corporation (IRMD)
About IRadimed Corporation
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system. The company also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical support representatives, and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 65.56M | 53.30M | 41.81M | 31.72M | 38.52M | 30.44M | 23.08M | 32.50M | 31.59M | 15.65M | 11.34M | 7.69M |
| Cost of Revenue | 15.40M | 12.02M | 9.76M | 8.14M | 8.82M | 7.21M | 5.57M | 6.15M | 5.84M | 3.40M | 2.85M | 2.13M |
| Gross Profit | 50.16M | 41.28M | 32.05M | 23.57M | 29.70M | 23.23M | 17.51M | 26.34M | 25.75M | 12.25M | 8.49M | 5.56M |
| Gross Profit Ratio | 76.50% | 77.45% | 76.65% | 74.33% | 77.11% | 76.31% | 75.87% | 81.06% | 81.51% | 78.25% | 74.84% | 72.34% |
| Research & Development | 2.86M | 2.28M | 1.91M | 1.90M | 1.43M | 1.52M | 1.72M | 1.35M | 1.76M | 1.07M | 1.01M | 654.07K |
| General & Administrative | 15.12M | 10.70M | 9.77M | 12.27M | 10.45M | 8.71M | 9.00M | 8.80M | 7.77M | 4.82M | 2.39M | 1.55M |
| Selling & Marketing | 12.14M | 12.68M | 10.56M | 10.16M | 9.17M | 7.00M | 5.50M | 5.28M | 4.71M | 3.30M | 2.30M | 1.93M |
| SG&A | 27.26M | 23.38M | 20.33M | 22.43M | 19.62M | 15.71M | 14.50M | 14.07M | 12.48M | 8.11M | 4.69M | 3.48M |
| Other Expenses | 0.00 | 553.10K | 18.61K | 139.21K | 395.91K | 193.54K | 111.38K | 32.68K | 121.39K | -48.55K | -3.46K | 7.42K |
| Operating Expenses | 30.12M | 25.65M | 22.23M | 24.33M | 21.05M | 17.22M | 16.23M | 15.42M | 14.24M | 9.18M | 5.70M | 4.13M |
| Cost & Expenses | 45.53M | 37.68M | 32.00M | 32.47M | 29.87M | 24.44M | 21.80M | 21.58M | 20.08M | 12.59M | 8.55M | 6.26M |
| Interest Income | 1.86M | 581.85K | 34.81K | 132.19K | 388.80K | 238.11K | 122.58K | 126.42K | 148.91K | 5.70K | 0.00 | 0.00 |
| Interest Expense | 0.00 | 581.85K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 765.18K | 670.67K | 634.01K | 603.60K | 591.18K | 559.73K | 445.27K | 248.30K | 223.94K | 149.06K | 139.04K | 106.28K |
| EBITDA | 20.80M | 16.30M | 11.22M | 582.73K | 9.89M | 7.11M | 2.59M | 11.17M | 11.51M | 3.21M | 2.93M | 1.53M |
| EBITDA Ratio | 31.73% | 29.32% | 26.84% | 1.84% | 25.68% | 23.35% | 11.24% | 34.37% | 37.15% | 20.54% | 25.80% | 19.92% |
| Operating Income | 20.04M | 15.63M | 9.82M | -756.09K | 8.65M | 6.00M | 1.29M | 10.92M | 11.51M | 3.07M | 2.79M | 1.42M |
| Operating Income Ratio | 30.56% | 29.32% | 23.48% | -2.38% | 22.45% | 19.72% | 5.57% | 33.60% | 36.44% | 19.59% | 24.58% | 18.54% |
| Total Other Income/Expenses | 1.70M | 553.10K | 18.61K | 139.21K | 395.91K | 193.54K | 111.38K | 32.68K | 121.39K | -48.55K | -3.46K | 7.42K |
| Income Before Tax | 21.74M | 16.18M | 9.84M | -616.88K | 9.04M | 6.20M | 1.40M | 10.95M | 11.63M | 3.02M | 2.78M | 1.43M |
| Income Before Tax Ratio | 33.16% | 30.36% | 23.52% | -1.94% | 23.48% | 20.36% | 6.05% | 33.70% | 36.83% | 19.28% | 24.55% | 18.63% |
| Income Tax Expense | 4.55M | 3.35M | 510.82K | -1.99M | -587.64K | -106.14K | 896.62K | 3.74M | 4.10M | 966.98K | 846.88K | 465.98K |
| Net Income | 17.19M | 12.83M | 9.33M | 1.37M | 9.63M | 6.30M | 499.76K | 7.21M | 7.53M | 2.05M | 1.94M | 966.09K |
| Net Income Ratio | 26.22% | 24.07% | 22.30% | 4.32% | 25.00% | 20.71% | 2.17% | 22.20% | 23.83% | 13.10% | 17.08% | 12.57% |
| EPS | 1.36 | 1.02 | 0.76 | 0.11 | 0.85 | 0.52 | 0.05 | 0.67 | 0.68 | 0.23 | 0.19 | 0.09 |
| EPS Diluted | 1.35 | 1.02 | 0.74 | 0.11 | 0.78 | 0.52 | 0.04 | 0.60 | 0.60 | 0.20 | 0.19 | 0.09 |
| Weighted Avg Shares Out | 12.60M | 12.56M | 12.35M | 12.12M | 11.28M | 12.11M | 10.64M | 10.82M | 11.00M | 8.74M | 10.42M | 10.42M |
| Weighted Avg Shares Out (Dil) | 12.72M | 12.64M | 12.59M | 12.44M | 12.28M | 12.11M | 11.72M | 11.99M | 12.56M | 10.22M | 10.42M | 10.42M |
IRADIMED CORPORATION Announces First Quarter 2021 Financial Results
WINTER SPRINGS, Fla., April 30, 2021 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and the only known provider of a non-magnetic intravenous (“IV”) infusion pump...
IRADIMED CORPORATION to Hold 2021 First Quarter Financial Results Conference Call on April 30th
WINTER SPRINGS, Fla., April 09, 2021 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2021 first quarter financial results before the market opens on Friday, April 30th. IRADIMED management will host a conference call the same...
IRadimed's (IRMD) CEO Roger Susi on Q4 2020 Results - Earnings Call Transcript
IRadimed's (IRMD) CEO Roger Susi on Q4 2020 Results - Earnings Call Transcript
IRADIMED CORPORATION to Hold 2020 Fourth Quarter Financial Results Conference Call on February 4th
WINTER SPRINGS, Fla., Jan. 27, 2021 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2020 fourth quarter financial results before the market opens on Thursday, February 4th. IRADIMED management will host a conference call the same...
IRadimed Corporation's (IRMD) CEO Roger Susi On Q3 2020 Results - Quick Version Earnings Call Transcript
IRadimed Corporation's (IRMD) CEO Roger Susi On Q3 2020 Results - Quick Version Earnings Call Transcript
IRADIMED CORPORATION Announces Third Quarter 2020 Financial Results
WINTER SPRINGS, Fla., Oct. 30, 2020 (GLOBE NEWSWIRE) -- iRadimed Corporation (the “Company”) (NASDAQ: IRMD), a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and the only known provider of a non-magnetic intravenous (“IV”) infusion pump...
Infusion Pump Market 2020 Industry Analysis, Forthcoming Growth, Industry Prospects and Forecast to 2030
Oct 09, 2020 (Profound via COMTEX) -- InsightSLICE report, titled Infusion Pump Market provides the definition, key players, major drivers, regional...
Materials for Infusion Disposables Market Size 2020–Global Industry Analysis, Trends, Market Demand, Growth, Opportunities and Forecast 2026
Oct 08, 2020 (The Expresswire) -- Global Materials for Infusion Disposables Market 2020 Report shows supply and demand values, revenue, production, imports...
Email Marketing Software Market 2020 Global Industry Size, Demand, Share, Growth Analysis, CAGR Status, Revenue and 2026 Forecast
Oct 01, 2020 (The Expresswire) -- Fortune Business Insights offers a detailed overview of the global market in a report, titledThe globalemail marketing...
Source: https://incomestatements.info
Category: Stock Reports